US OptionsDetailed Quotes

IVVD241220C5000

Watchlist
  • 0.03
  • 0.000.00%
15min DelayClose Nov 21 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    Nov 14 06:03
    NEWS
    $Invivyd (IVVD.US)$
    Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
    The New England Journal of Medicine (NEJM) published a Letter to the Editor describing PEMGARDA™ (pemivibart)'s immunobridging emergency use authorization pathway and an updated correlate of protection curve for COVID-19 prevention. The letter...
    Trytosaveabit
    Trytosaveabit
    Nov 12 07:38
    Update
    $Invivyd (IVVD.US)$ Benzinga· 3 mins ago
    Invivyd Publishes CANOPY Phase 3 Trial Data Preprints Showing Long-Term COVID-19 Protection By Pemivibart Against JN.1 Sublineages; Novel Method For Predicting Monoclonal Antibody Activity Against Emerging Variants Detailed In BioRxiv
    Trytosaveabit
    Trytosaveabit
    Oct 29 06:14
    Update
    $Invivyd (IVVD.US)$ Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (Pemivibart) Provided Substantial Protection From Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
    GlobeNewswire· 12 mins ago
    Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month pe...
    Jaguar8
    Jaguar8
    Oct 16 06:41
    NEWS
    $Invivyd (IVVD.US)$
    Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
    Invivyd (Nasdaq: IVVD) announced upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024 in Los Angeles, October 16-19, 2024. The presentations include:
    An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
    A poster on results from a Phase 1 first-in-human study
    A poster on pharmacokinetics and serum virus neutral...
    1
Read more